Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07000123 · ClinicalTrials.gov registry record · Phase 3

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

A Phase 3 study of Cardiovascular Disease, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
3,046
Enrollment target
20
Study locations

NCT07000123 is a Phase 3 study of Cardiovascular Disease that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 3,046 participants, above the 2,691-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (13% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07000123, a Phase 3 study of Cardiovascular Disease, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
3,046 participants
Enrollment target
20
Study locations

Study Summary

This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.

Conditions Studied

Cardiovascular Disease

Interventions

  • DRUG Placebo
  • DRUG AZD0780

Study Locations (20)

California

  • Research Site - Garden Grove
  • Research Site - Gardena
  • Research Site - Lancaster
  • Research Site - Lincoln
  • Research Site - San Diego
  • Research Site - San Diego
  • Research Site - Torrance
  • Research Site - West Hills

Florida

  • Research Site - Boca Raton
  • Research Site - Hallandale
  • Research Site - Hialeah
  • Research Site - Inverness
  • Research Site - Jacksonville

Alabama

  • Research Site - Huntsville
  • Research Site - Irondale
  • Research Site - Mobile

Arizona

  • Research Site - Gilbert
  • Research Site - Phoenix
  • Research Site - Sun City West

Connecticut

  • Research Site - Hamden

Trial Details

FieldValue
Enrollment Target 3,046 participants
Start Date 2025-05-28
Est. Completion 2027-01-11
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07000123

The ClinicalTrials.gov registry entry for NCT07000123 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 3,046 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,691-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (13% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07000123 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT07000123 about?

NCT07000123 is a clinical study titled "A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event". This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the partici...

What is the current status of trial NCT07000123?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 3,046 participants. The study started on 2025-05-28. Estimated completion is 2027-01-11.

What conditions does trial NCT07000123 study?

This clinical trial studies the following conditions: Cardiovascular Disease.

What interventions are being tested in trial NCT07000123?

The interventions under investigation include: Placebo (DRUG), AZD0780 (DRUG).

Who is sponsoring clinical trial NCT07000123?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07000123 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cardiovascular Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cardiovascular Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.